JP7754455B2 - Ｔｈ２介在性疾患を治療または予防するためのＰＤ－１アゴニスト含有医薬組成物 - Google Patents

Ｔｈ２介在性疾患を治療または予防するためのＰＤ－１アゴニスト含有医薬組成物

Info

Publication number
JP7754455B2
JP7754455B2 JP2022526545A JP2022526545A JP7754455B2 JP 7754455 B2 JP7754455 B2 JP 7754455B2 JP 2022526545 A JP2022526545 A JP 2022526545A JP 2022526545 A JP2022526545 A JP 2022526545A JP 7754455 B2 JP7754455 B2 JP 7754455B2
Authority
JP
Japan
Prior art keywords
cells
human
antibody
antibodies
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022526545A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021241523A1 (https=
Inventor
佑 本庶
明夫 太田
正樹 但馬
春彦 鎌田
諭志 永田
健介 鈴木
裕也 大城
陽介 徳丸
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Seika Kaisha Ltd
Original Assignee
Meiji Seika Kaisha Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha Ltd filed Critical Meiji Seika Kaisha Ltd
Publication of JPWO2021241523A1 publication Critical patent/JPWO2021241523A1/ja
Application granted granted Critical
Publication of JP7754455B2 publication Critical patent/JP7754455B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2022526545A 2020-05-25 2021-05-24 Ｔｈ２介在性疾患を治療または予防するためのＰＤ－１アゴニスト含有医薬組成物 Active JP7754455B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020090526 2020-05-25
JP2020090526 2020-05-25
PCT/JP2021/019676 WO2021241523A1 (ja) 2020-05-25 2021-05-24 Ｔｈ２介在性疾患を治療または予防するためのＰＤ－１アゴニスト含有医薬組成物

Publications (2)

Publication Number Publication Date
JPWO2021241523A1 JPWO2021241523A1 (https=) 2021-12-02
JP7754455B2 true JP7754455B2 (ja) 2025-10-15

Family

ID=78744780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022526545A Active JP7754455B2 (ja) 2020-05-25 2021-05-24 Ｔｈ２介在性疾患を治療または予防するためのＰＤ－１アゴニスト含有医薬組成物

Country Status (7)

Country Link
US (1) US20230183347A1 (https=)
EP (1) EP4159235A4 (https=)
JP (1) JP7754455B2 (https=)
KR (1) KR20230015348A (https=)
CN (1) CN115697405A (https=)
TW (1) TWI890796B (https=)
WO (1) WO2021241523A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220596A (es) 2020-05-26 2023-01-23 Boehringer Ingelheim Int Anticuerpos anti-pd-1
WO2022239820A1 (ja) * 2021-05-13 2022-11-17 公益財団法人神戸医療産業都市推進機構 炎症性疾患を治療又は予防するための抗ヒトｐｄ－１アゴニスト抗体及びこれを含有する医薬組成物
KR20240137086A (ko) * 2022-01-28 2024-09-19 조지아뮨 인코포레이티드 Pd-1 작용제인 세포예정사 단백질 1에 대한 항체

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013022091A1 (ja) 2011-08-11 2013-02-14 小野薬品工業株式会社 Ｐｄ－１アゴニストからなる自己免疫疾患治療剤
CN106924718A (zh) 2017-04-27 2017-07-07 中山大学 B7‑dc突变体在治疗哮喘中的应用
CN107149680A (zh) 2017-04-27 2017-09-12 中山大学 Pd‑1h激动剂在哮喘治疗中的应用
WO2019168745A1 (en) 2018-03-02 2019-09-06 Eli Lilly And Company Pd-1 agonist antibodies and uses thereof
JP2019531284A (ja) 2016-09-19 2019-10-31 セルジーン コーポレイション Ｐｄ−１結合タンパク質を使用して免疫障害を治療する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105142672B (zh) 2012-10-23 2019-04-05 西纳福克斯股份有限公司 经修饰的抗体、抗体-缀合物及其制备方法
CN107149530A (zh) * 2016-03-04 2017-09-12 吴东 一种洗头装置
WO2022239820A1 (ja) * 2021-05-13 2022-11-17 公益財団法人神戸医療産業都市推進機構 炎症性疾患を治療又は予防するための抗ヒトｐｄ－１アゴニスト抗体及びこれを含有する医薬組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013022091A1 (ja) 2011-08-11 2013-02-14 小野薬品工業株式会社 Ｐｄ－１アゴニストからなる自己免疫疾患治療剤
JP2019531284A (ja) 2016-09-19 2019-10-31 セルジーン コーポレイション Ｐｄ−１結合タンパク質を使用して免疫障害を治療する方法
CN106924718A (zh) 2017-04-27 2017-07-07 中山大学 B7‑dc突变体在治疗哮喘中的应用
CN107149680A (zh) 2017-04-27 2017-09-12 中山大学 Pd‑1h激动剂在哮喘治疗中的应用
WO2019168745A1 (en) 2018-03-02 2019-09-06 Eli Lilly And Company Pd-1 agonist antibodies and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Cureus，2017年，vol.9, issue 4，e1177. p.1-11
Eur. J. Immunol.，2004年，vol.34, issue 12，p.3326-3336
Eur. J. Immunol.，2015年，vol.45, issue 4，p.1019-1029
Gut，2015年，vol.64, issue 2，p.260-271
Mucosal Immunol.，2013年，vol.6, no.4，p.728-739

Also Published As

Publication number Publication date
US20230183347A1 (en) 2023-06-15
TW202210099A (zh) 2022-03-16
CN115697405A (zh) 2023-02-03
EP4159235A1 (en) 2023-04-05
TWI890796B (zh) 2025-07-21
KR20230015348A (ko) 2023-01-31
EP4159235A4 (en) 2024-07-10
JPWO2021241523A1 (https=) 2021-12-02
WO2021241523A1 (ja) 2021-12-02

Similar Documents

Publication Publication Date Title
JP7047172B2 (ja) 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
JP7061235B2 (ja) 抗ｃｌｄ１８ａ２ナノ抗体及びその応用
RU2203682C2 (ru) Фармацевтическая композиция для лечения иммунных заболеваний
CA2955541C (en) Anti-pd-1 antibody and use thereof
KR101704865B1 (ko) 항-ox40 항체 및 그의 용도
Brightbill et al. Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice
JP7754455B2 (ja) Ｔｈ２介在性疾患を治療または予防するためのＰＤ－１アゴニスト含有医薬組成物
CN106939049B (zh) 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用
US20120301484A1 (en) Regulatory t cell mediator proteins and uses thereof
CN107073109A (zh) Vista激动剂和拮抗剂抑制或增强体液免疫的用途
US20040092718A1 (en) Use of a CD28 binding substance for making a pharmaceutical composition
JP2017519494A (ja) Ｏｘ４０ｌ融合タンパク質およびその使用
KR20190115079A (ko) 암 요법 및 b 세포 장애에서의 항-bcma 항체 및 항체-커플링된 t 세포 수용체 (actr)의 공동-사용
US20250041416A1 (en) P329g antibody targeting bcma, combination of same with chimeric antigen receptor cell, and use thereof
US20230015969A1 (en) Regulatory t cell mediator proteins and uses thereof
CN116162168A (zh) 分子开关调控型嵌合抗原受体细胞和抗体的组合及其应用
JP2840131B2 (ja) 液性免疫の持続性抑制方法
CN114025757B (zh) 人源化抗pd-l1抗体
CN102471381A (zh) 自身免疫性脱髓鞘疾病的诊断和治疗
WO2025201418A1 (en) Engineered immune cells and uses thereof
TW202540189A (zh) 在組合療法中能夠結合ｏｘ４０之抗體
WO2024140836A1 (zh) 靶向nkg2d配体的融合蛋白与嵌合抗原受体细胞的组合及其用途
WO2024169985A1 (zh) 靶向HER2/p95HER2的P329G抗体及其与嵌合抗原受体细胞的组合和应用
TW202607042A (zh) 多特異性抗原結合蛋白
HK40113958A (zh) 包含cd4结合部分的免疫细胞受体

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250519

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250902

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250924

R150 Certificate of patent or registration of utility model

Ref document number: 7754455

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150